SLS Collar Strategy
SLS (SELLAS Life Sciences Group, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
SLS (SELLAS Life Sciences Group, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $930.1M, a beta of 2.24 versus the broader market, a 52-week range of 1.39-6.72, average daily share volume of 6.3M, a public-listing history dating back to 2008, approximately 15 full-time employees. These structural characteristics shape how SLS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.24 indicates SLS has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a collar on SLS?
A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot.
Current SLS snapshot
As of May 15, 2026, spot at $7.06, ATM IV 150.40%, IV rank 33.98%, expected move 43.12%. The collar on SLS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this collar structure on SLS specifically: IV regime affects collar pricing on both sides; mid-range SLS IV at 150.40% typically pushes the short call premium to roughly offset the long put cost, with a market-implied 1-standard-deviation move of approximately 43.12% (roughly $3.04 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SLS expiries trade a higher absolute premium for lower per-day decay. Position sizing on SLS should anchor to the underlying notional of $7.06 per share and to the trader's directional view on SLS stock.
SLS collar setup
The SLS collar below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SLS near $7.06, the first option leg uses a $7.50 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SLS chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SLS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $7.06 | long |
| Sell 1 | Call | $7.50 | $1.05 |
| Buy 1 | Put | $6.50 | $0.75 |
SLS collar risk and reward
- Net Premium / Debit
- -$676.00
- Max Profit (per contract)
- $74.00
- Max Loss (per contract)
- -$26.00
- Breakeven(s)
- $6.76
- Risk / Reward Ratio
- 2.846
Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium.
SLS collar payoff curve
Modeled P&L at expiration across a range of underlying prices for the collar on SLS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -99.9% | -$26.00 |
| $1.57 | -77.8% | -$26.00 |
| $3.13 | -55.7% | -$26.00 |
| $4.69 | -33.6% | -$26.00 |
| $6.25 | -11.5% | -$26.00 |
| $7.81 | +10.6% | +$74.00 |
| $9.37 | +32.7% | +$74.00 |
| $10.93 | +54.8% | +$74.00 |
| $12.49 | +76.9% | +$74.00 |
| $14.05 | +99.0% | +$74.00 |
When traders use collar on SLS
Collars on SLS hedge an existing long SLS stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
SLS thesis for this collar
The market-implied 1-standard-deviation range for SLS extends from approximately $4.02 on the downside to $10.10 on the upside. A SLS collar hedges an existing long SLS position with a protective put while financing the put cost via a short call; when the premiums roughly offset, the collar acts as a near-zero-cost insurance band around the current spot. Current SLS IV rank near 33.98% is mid-range against its 1-year distribution, so the IV signal is neutral; the collar thesis on SLS should anchor more to the directional view and the expected-move geometry. As a Healthcare name, SLS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SLS-specific events.
SLS collar positions are structurally neutral (protective); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SLS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SLS alongside the broader basket even when SLS-specific fundamentals are unchanged. Always rebuild the position from current SLS chain quotes before placing a trade.
Frequently asked questions
- What is a collar on SLS?
- A collar on SLS is the collar strategy applied to SLS (stock). The strategy is structurally neutral (protective): A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot. With SLS stock trading near $7.06, the strikes shown on this page are snapped to the nearest listed SLS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are SLS collar max profit and max loss calculated?
- Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the SLS collar priced from the end-of-day chain at a 30-day expiry (ATM IV 150.40%), the computed maximum profit is $74.00 per contract and the computed maximum loss is -$26.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a SLS collar?
- The breakeven for the SLS collar priced on this page is roughly $6.76 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SLS market-implied 1-standard-deviation expected move is approximately 43.12%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a collar on SLS?
- Collars on SLS hedge an existing long SLS stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
- How does current SLS implied volatility affect this collar?
- SLS ATM IV is at 150.40% with IV rank near 33.98%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.